Endocyte, Inc. (NASDAQ:ECYT) saw a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 1,132,626 shares, a decrease of 54.0% from the June 15th total of 2,462,281 shares. Currently, 3.3% of the company’s shares are short sold. Based on an average daily trading volume, of 940,842 shares, the days-to-cover ratio is presently 1.2 days.

Shares of Endocyte (ECYT) opened at 1.45 on Monday. Endocyte has a one year low of $1.36 and a one year high of $3.49. The company’s market capitalization is $61.58 million. The company has a 50-day moving average price of $2.04 and a 200 day moving average price of $2.28.

Endocyte (NASDAQ:ECYT) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.01. The company had revenue of $0.01 million for the quarter. Endocyte had a negative return on equity of 29.67% and a negative net margin of 59,808.57%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.24) earnings per share. Equities analysts anticipate that Endocyte will post ($0.89) EPS for the current year.

A number of institutional investors have recently made changes to their positions in the company. Stifel Financial Corp boosted its position in shares of Endocyte by 3.9% in the first quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,711 shares during the period. Two Sigma Investments LP bought a new position in shares of Endocyte during the fourth quarter worth approximately $140,000. Stoneridge Investment Partners LLC boosted its position in shares of Endocyte by 40.0% in the first quarter. Stoneridge Investment Partners LLC now owns 57,406 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16,399 shares during the period. Teachers Advisors LLC boosted its position in shares of Endocyte by 17.1% in the fourth quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 9,506 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Endocyte by 26.7% in the first quarter. Ameriprise Financial Inc. now owns 133,270 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 28,110 shares during the period. 33.04% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently issued reports on ECYT shares. Zacks Investment Research raised Endocyte from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Thursday, June 8th. Cowen and Company reaffirmed a “buy” rating on shares of Endocyte in a research note on Wednesday, April 5th. Wedbush downgraded Endocyte from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $8.00 to $2.00 in a research note on Monday, June 5th. Finally, ValuEngine downgraded Endocyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $3.58.

WARNING: “Endocyte, Inc. (NASDAQ:ECYT) Short Interest Update” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/17/endocyte-inc-nasdaqecyt-short-interest-update.html.

Endocyte Company Profile

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.